SEARCH:   Advanced

Blood, 15 October 2005, Vol. 106, No. 8, pp. 2862-2864. Prepublished online as a Blood First Edition Paper on June 28, 2005; DOI 10.1182/blood-2005-04-1515. This Article Full Text (PDF) All Versions of this Article: 2005-04-1515v1 106/8/2862    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Goerttler, P. S Articles by Pahl, H. L Search for Related Content PubMed PubMed Citation Articles by Goerttler, P. S Articles by Pahl, H. L Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 14, 2005 Accepted June 14, 2005 The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients Philipp S Goerttler, Cordula Steimle, Edith Marz, Peter L Johansson, Bjorn Andreasson, Martin Griesshammer, Heinz Gisslinger, Hermann Heimpel, and Heike L Pahl* Department of Experimental Anaesthesiology, University Hospital Freiburg, Freiburg, Germany Department of Medicine, University of Goteborg, Goteborg, Sweden Department of Medicine III, University Hospital Ulm, Ulm, Germany Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria Department of Experimental Anaesthesiology, University Hospital Freiburg, Freiburg, Germany; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria * Corresponding author; email: pahl{at}uni-freiburg.de. Recently, a Jak2V617F mutation has been described in the vast majority of patients with polycythemia vera (PV) as well as in subsets of patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). The question arises whether this mutation is observed in that subset of ET and IMF patients which carries previously described molecular markers, notably the ability to form endogenous erythroid colonies (EECs), overexpression of PRV-1 and decreased c-Mpl expression. We therefore analyzed the Jak2 DNA sequence, EEC growth, PRV-1 expression and c-Mpl levels in a cohort of 78 MPD patients (42 ET, 22 PV and 14 IMF). Presence of the Jak2V617F mutation was very highly correlated with PRV-1 overexpression and the ability to form EECs in all three subtypes of MPD (p<0.0001). CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Let's not get too JAKed up! Ronald Hoffman Blood 2005 106: 2599. [Full Text] [PDF] This article has been cited by other articles: L. Pieri, C. Bogani, P. Guglielmelli, M. Zingariello, R. A. Rana, N. Bartalucci, A. Bosi, and A. M. Vannucchi The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera Haematologica, November 1, 2009; 94(11): 1537 - 1545. [Abstract] [Full Text] [PDF] V. Senyuk, C. R. Rinaldi, D. Li, F. Cattaneo, A. Stojanovic, F. Pane, X. Du, N. Mahmud, J. Dickstein, and G. Nucifora Consistent Up-regulation of Stat3 Independently of Jak2 Mutations in a New Murine Model of Essential Thrombocythemia Cancer Res., January 1, 2009; 69(1): 262 - 271. [Abstract] [Full Text] [PDF] L. Teofili, F. Giona, M. Martini, T. Cenci, F. Guidi, L. Torti, G. Palumbo, A. Amendola, R. Foa, and L. M. Larocca Markers of Myeloproliferative Diseases in Childhood Polycythemia Vera and Essential Thrombocythemia J. Clin. Oncol., March 20, 2007; 25(9): 1048 - 1053. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF] A. R. Moliterno, D. M. Williams, O. Rogers, and J. L. Spivak Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression Blood, December 1, 2006; 108(12): 3913 - 3915. [Abstract] [Full Text] [PDF] T. Ishii, E. Bruno, R. Hoffman, and M. Xu Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera Blood, November 1, 2006; 108(9): 3128 - 3134. [Abstract] [Full Text] [PDF] E. Lippert, M. Boissinot, R. Kralovics, F. Girodon, I. Dobo, V. Praloran, N. Boiret-Dupre, R. C. Skoda, and S. Hermouet The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera Blood, September 15, 2006; 108(6): 1865 - 1867. [Abstract] [Full Text] [PDF] D. P. Steensma JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2006; 8(4): 397 - 411. [Abstract] [Full Text] [PDF] G. Wernig, T. Mercher, R. Okabe, R. L. Levine, B. H. Lee, and D. G. Gilliland Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model Blood, June 1, 2006; 107(11): 4274 - 4281. [Abstract] [Full Text] [PDF] R. L. Levine, C. Belisle, M. Wadleigh, D. Zahrieh, S. Lee, P. Chagnon, D. G. Gilliland, and L. Busque X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis Blood, May 15, 2006; 107(10): 4139 - 4141. [Abstract] [Full Text] [PDF] A. V. Jones, R. T. Silver, K. Waghorn, C. Curtis, S. Kreil, K. Zoi, A. Hochhaus, D. Oscier, G. Metzgeroth, E. Lengfelder, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha Blood, April 15, 2006; 107(8): 3339 - 3341. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020